Screener
Climb Bio, Inc. CLYM CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Climb Bio, Inc.’s 10-Q, filed November 6, 2025.
- Filed
- Nov 6, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-268086
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Long-term liabilities | — | (22) |
| Net cash used in operating activities | (38,721) | (10,041) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (186) | — |
| Purchases of marketable securities | (103,082) | (71,789) |
| Maturities of marketable securities | 80,563 | 13,751 |
| Issuance of promissory loan in connection with asset acquisition | — | (5,000) |
| Cash paid in connection with asset acquisition, net of cash received | — | (4,645) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s capex?
- Climb Bio, Inc. (CLYM) reported capex of $109K in Q3 2025.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Climb Bio, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude